The aim of this study is to establish a clinical score panel based on clinical, molecular and genetic parameters that allow us to stratify and obtain an early detection of patients with an increased risk of developing hepatocellular carcinoma (HCC).
Transversal study design like a "proof of concept". Primary objective: The main objective is try to stablish a descriptive panel (first phase of a score system) based in the conjunction or sum of several clinical and laboratory parameters (molecular and genetic factors). The aim is to detect in a fast, early and successful way those patients that presents a high risk to develop an hepatocellular carcinoma (HCC) in the future in a specific population: HIV and HCV coinfected patients. The establishment of this panel will allow clinicians set up a correct treatment decreasing the probability of liver cirrhosis and HCC.
Study Type
OBSERVATIONAL
Enrollment
45
Hospital Ramón y Cajal
Madrid, Spain
Sera inflammatory markers
Inflammatory markers will be measure used a Enzyme-linked Immunosorbent Assay
Time frame: 1 day (Routine visit to normal following in Infectious Disease Department)
Sera apoptotic markers
Apoptotic markers will be evaluated through a Enzyme-linked Immunosorbent Assay
Time frame: 1 day (Routine visit in disease following at Infectious Disease Department)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.